169 related articles for article (PubMed ID: 21788135)
81. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
Yamamoto N; Ohrui S; Okada T; Yata M; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4176-4179. PubMed ID: 28739044
[TBL] [Abstract][Full Text] [Related]
82. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
83. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
84. The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities.
Li W; Long JD; Qian YY; Long Y; Xu XJ; Wang YJ; Shen Q; Wang ZN; Yang XC; Xiao L; Sun HP; Xu YL; Chen YY; Xie Q; Wang YH; Shao LM; Liu JG; Qiu ZB; Fu W
ACS Chem Neurosci; 2017 Apr; 8(4):766-776. PubMed ID: 28033462
[TBL] [Abstract][Full Text] [Related]
85. Spinal delta-opioid receptors mediate suppression of systemic SNC80 on excitability of the flexor reflex in normal and inflamed rat.
Cao CQ; Hong Y; Dray A; Perkins M
Eur J Pharmacol; 2001 Apr; 418(1-2):79-87. PubMed ID: 11334868
[TBL] [Abstract][Full Text] [Related]
86. Chemistry of opium alkaloids. Part 44: synthesis and opioid receptor binding profile of substituted ethenoisomorphinans and ethenomorphinans.
Maat L; Woudenberg RH; Meuzelaar GJ; Linders JT
Bioorg Med Chem; 1999 Mar; 7(3):529-41. PubMed ID: 10220038
[TBL] [Abstract][Full Text] [Related]
87. The most effective influence of 17-(3-ethoxypropyl) substituent on the binding affinity and the agonistic activity in KNT-127 derivatives, δ opioid receptor agonists.
Nemoto T; Ida Y; Iihara Y; Nakajima R; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem; 2013 Dec; 21(24):7628-47. PubMed ID: 24262888
[TBL] [Abstract][Full Text] [Related]
88. Design, synthesis, pharmacological evaluation and molecular dynamics of β-amino acids morphan-derivatives as novel ligands for opioid receptors.
Nieto CT; Gonzalez-Nunez V; Rodríguez RE; Diez D; Garrido NM
Eur J Med Chem; 2015 Aug; 101():150-62. PubMed ID: 26134550
[TBL] [Abstract][Full Text] [Related]
89. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
Bileviciute-Ljungar I; Spetea M; Guo Y; Schütz J; Windisch P; Schmidhammer H
J Pharmacol Exp Ther; 2006 Apr; 317(1):220-7. PubMed ID: 16339394
[TBL] [Abstract][Full Text] [Related]
90. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
Nagase H; Hayakawa J; Kawamura K; Kawai K; Takezawa Y; Matsuura H; Tajima C; Endo T
Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):366-9. PubMed ID: 9501472
[TBL] [Abstract][Full Text] [Related]
91. Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators.
Ma H; Obeng S; Wang H; Zheng Y; Li M; Jali AM; Stevens DL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2019 Dec; 62(24):11399-11415. PubMed ID: 31782922
[TBL] [Abstract][Full Text] [Related]
92. Receptor reserve reflects differential intrinsic efficacy associated with opioid diastereomers.
Carliss RD; Keefer JF; Perschke S; Welch S; Rich TC; Weissman AD
Pharmacol Biochem Behav; 2009 May; 92(3):495-502. PubMed ID: 19463265
[TBL] [Abstract][Full Text] [Related]
93. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
94. Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists.
Ida Y; Nemoto T; Hirayama S; Fujii H; Osa Y; Imai M; Nakamura T; Kanemasa T; Kato A; Nagase H
Bioorg Med Chem; 2012 Jan; 20(2):949-61. PubMed ID: 22197670
[TBL] [Abstract][Full Text] [Related]
95. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.
Nagase H; Yamamoto N; Yata M; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ishikawa Y; Ogawa Y; Hirayama S; Kuroda D; Watanabe Y; Gouda H; Yanagisawa M
J Med Chem; 2017 Feb; 60(3):1018-1040. PubMed ID: 28051300
[TBL] [Abstract][Full Text] [Related]
96. Guanidino N-substituted and N,N-disubstituted derivatives of the kappa-opioid antagonist GNTI.
Black SL; Chauvignac C; Grundt P; Miller CN; Wood S; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2003 Dec; 46(25):5505-11. PubMed ID: 14640558
[TBL] [Abstract][Full Text] [Related]
97. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
98. Characterization of BU09059: a novel potent selective κ-receptor antagonist.
Casal-Dominguez JJ; Furkert D; Ostovar M; Teintang L; Clark MJ; Traynor JR; Husbands SM; Bailey SJ
ACS Chem Neurosci; 2014 Mar; 5(3):177-84. PubMed ID: 24410326
[TBL] [Abstract][Full Text] [Related]
99. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
100. Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.
Manglik A; Kruse AC; Kobilka TS; Thian FS; Mathiesen JM; Sunahara RK; Pardo L; Weis WI; Kobilka BK; Granier S
Nature; 2012 Mar; 485(7398):321-6. PubMed ID: 22437502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
